Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Intangibles (2018 - 2025)

Autolus Therapeutics' Intangibles history spans 6 years, with the latest figure at $19.8 million for Q4 2025.

  • For Q4 2025, Intangibles rose 60.1% year-over-year to $19.8 million; the TTM value through Dec 2025 reached $19.8 million, up 60.1%, while the annual FY2025 figure was $19.8 million, 60.1% up from the prior year.
  • Intangibles reached $19.8 million in Q4 2025 per AUTL's latest filing, down from $20.3 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $20.3 million in Q3 2025 to a low of $65000.0 in Q4 2021.
  • Average Intangibles over 3 years is $13.0 million, with a median of $12.7 million recorded in 2025.
  • Peak YoY movement for Intangibles: plummeted 58.86% in 2021, then soared 60.1% in 2025.
  • A 3-year view of Intangibles shows it stood at $65000.0 in 2021, then soared by 18935.38% to $12.4 million in 2024, then skyrocketed by 60.1% to $19.8 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Intangibles are $19.8 million (Q4 2025), $20.3 million (Q3 2025), and $12.9 million (Q2 2025).